Application of Cancer Vaccines of IEPOR Series into Clinical Practice of Oncological Establishments of Ukraine
DOI:
https://doi.org/10.15407/scin5.01.062Keywords:
cancer vaccine, immunotherapy of cancer, oncological patients, survivalAbstract
The article presents the review of clinical studies dealing with effectiveness of anticancer vaccines based on whole autologous or allogenic tumor cells or their lysates. The main results of clinical investigations of produced at R.Ye. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology (National Academy of Sciences of Ukraine) anticancer vaccines based on autologous tumor cells and metabolic products of B.subtilis are described.
References
Berzofsky J.A., Terabe M., Oh S. et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest. 2004. 113(11): 1515-1525.
https://doi.org/10.1172/JCI21926
Rosenberg S. Progress in human tumor immunology and immunotherapy. Nature. 2001. 411(6835): 380-384.
https://doi.org/10.1038/35077246
Espinoza-Delgado I. Cancer vaccines. Oncologist. 2002. Vol. 7, Suppl. 3. P. 20-33.
https://doi.org/10.1634/theoncologist.7-suppl_3-20
Pandey M., Mathew A., Nair M.K. Cancer vaccine: a step toward prevention and treatment of cancer. Europ J Surg Oncol. 1999. Vol. 25. P. 209-214.
https://doi.org/10.1053/ejso.1998.0629
Armstrong A.C., Hawkins R.E. Vaccines in oncology: background and clinical potential. Brit J Radiol. 2001. 74(887): 991-1002.
https://doi.org/10.1259/bjr.74.887.740991
Horig H., Kaufman H.L. Current issues in cancer vaccine development. Clin Immunol. 1999. 92(3): 211-223.
https://doi.org/10.1006/clim.1999.4751
Slingluff C.L. Jr., Speiser D.E. Progress and controversies in developing cancer vaccines. J Transl Med. 2005. 3(1): 18-26.
https://doi.org/10.1186/1479-5876-3-18
Conry R.M., LoBuglio A.F., Loechel F. et al. A carcinoembrypnic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther. 1995. 2(1): 59-65.
Livingston P.O. Approaches to augmenting the immunogenecity of melanoma gangliosides: From whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev. 1995. 145(1): 147-166.
https://doi.org/10.1111/j.1600-065X.1995.tb00080.x
Baldueva I.A. Protivoopuholevye vakciny. Prakticheskaja onkologija. 2003. 4(3): 157-166 [in Russian].
Mosca P.J., Hobeika A.C., Clay T.M. et al. Direct detection of cellular immune responses to cancer vaccines. Surgery. 2001. 129(3): 248-254.
https://doi.org/10.1067/msy.2001.108609
Mitchell M.S. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol. 1998. 25(6): 623-635.
Moingeon G. Cancer vaccines. Vaccine. 2001. 19(11-12): 1305-1326.
https://doi.org/10.1016/S0264-410X(00)00372-8
Chen Y.T. Cancer vaccine: identification of human tumor antigens by SEREX. Cancer J. 2000. Vol. 6, Suppl 3. P. 208-217.
Engelhard V.H., Bullock T.N., Colella T.A., Mullins D.W. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use. Cancer J. 2000. Vol 6, Suppl 3. P. 272-280.
Gordan J.D., Vonderheide R.H. Universal tumor antigens as targets for immunotherapy. Cytotherapy. 2002. 4(4): 317-327.
https://doi.org/10.1080/146532402760271091
Liu M., Acres B., Balloul J.-M. et al. Gene-based vaccines and immunotherapeutics. PNAS. 2004. Vol. 101, suppl. 2. P. 14567-14571.
https://doi.org/10.1073/pnas.0404845101
Harris J.E., Ryan L., Hoover H.C.Jr. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: eastern cooperative oncology group study E5283. J Clin Oncol. 2000. 18(1): 148-157.
Hoover H.C.Jr., Brandhorst J.S., Peters L.C. et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6,5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol. 1993. 11(3): 390-399.
Repmann R., Goldschmidt A.J., Richter A. Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis. Anticancer Res. 2003. 23(2A): 969-974.
Berd D., Maguire H.C.Jr., Schuchter L.M. et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol. 1997. 15(6): 2359-2370.
Berd D., Kairys J., Dunton C. Autologous, hapten-modified vaccine as a treatment for human cancers. Semin Oncol. 1998. Vol. 25. P. 646-653.
Berd D., Sato T., Cohn H. et al. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int J Cancer. 2001. 94(4): 531-539.
https://doi.org/10.1002/ijc.1506.abs
Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Opin Biol Ther. 2002. 2(3): 335-342.
https://doi.org/10.1517/14712598.2.3.335
Berd D., Sato T., Maguire H.C.Jr. et al. Immunopharmacologic analysis of an autologous, hapten-odified human melanoma vaccine. J Clin Oncol. 2004. 22(3): 403-415.
https://doi.org/10.1200/JCO.2004.06.043
Hersey P., Coates A.S., McCarthy. W.H. et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol. 2002. 20(20): 4181-4190.
https://doi.org/10.1200/JCO.2002.12.094
Ockert D., Schirrmacher V., Beck N. et al. Newcastle disease virus_infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res. 1996. 2(1): 21-28.
Schirrmacher V., Haas C., Bonifer R. et al. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther. 1999. 6(1): 63-73.
https://doi.org/10.1038/sj.gt.3300787
Hanna M.G.Jr., Hoover H.C.Jr., Vermorken J.B. et al. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine. 2001. 19(17-19): 2576-2582.
https://doi.org/10.1016/S0264-410X(00)00485-0
Ransom J.H., Pelle B.A., Hubers H. et al. Identification of colon-tumor-associated antigens by T-cell lines derived from tumor-infiltrating lymphocytes and peripheralblood lymphocytes from patients immunized with an autologous tumor-cell with Bacillus Calmette-Querin vaccine. Int J Cancer. 1993. 54(5): 734-740.
https://doi.org/10.1002/ijc.2910540505
Vermorken J.B., Claessen A.M., van Tinteren H. et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet. 1999. 353(9150): 345-350.
https://doi.org/10.1016/S0140-6736(98)07186-4
Salgia R., Lynch T., Skarin A. et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003. 21(4): 624-630.
https://doi.org/10.1200/JCO.2003.03.091
Simons J.W., Mikhak B., Chang J.F. et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 1999. 59(20): 5160-5168.
Soiffer R., Lynch T., Mihm M. et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Nat Acad Sci USA. 1998. 95(22): 13141-13146.
https://doi.org/10.1073/pnas.95.22.13141
Soiffer R., Hodi F.S., Haluska F. et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol. 2003. 21(17): 3343-3350.
https://doi.org/10.1200/JCO.2003.07.005
Jocham D., Richter A., Hoffmann L. et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet. 2004. 363(9409): 594-599.
https://doi.org/10.1016/S0140-6736(04)15590-6
Kuang M., Peng B.G., Lu M.D. et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for post- surgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004. 10(5): 1574-1579.
https://doi.org/10.1158/1078-0432.CCR-03-0071
Uyl-de Groot C.A., Vermorken J.B., Hanna M.G.Jr. et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine. 2005. 23(17-18): 2379-2387.
https://doi.org/10.1016/j.vaccine.2005.01.015
Greten T.F., Jaffee E.M. Cancer vaccines. J Clin Oncol. 1999. 17(3): 1047-1060
McCune C.S., O'Donnell R.W., Marquis D.M., Sahasrabud he D.M. Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol Immunother. 1990. 32(1): 62-66.
https://doi.org/10.1007/BF01741726
Sinkovics J.G. Viral oncolysates as human tumor vaccine. Int Rev Immunol. 1991. Vol. 7. P. 259-287.
https://doi.org/10.3109/08830189109114875
Sivanandham M., Ditaranto K., Shaw P. et al. A phase III randomized, multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with melanoma — an overview. Vaccone Res. 1996. Vol. 5. P. 215-222.
Wallack M.K., Sivanandham M., Balch C.M. et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg. 1998. 187(1): 69-77.
https://doi.org/10.1016/S1072-7515(98)00097-0
Liang W., Wang H., Sun T.M. et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterol. 2003. 9(3): 495-498.
https://doi.org/10.3748/wjg.v9.i3.495
Schirrmacher V., Feuerer M., Beckhove P. et al. T cell memory, anergy and immunotherapy in breast cancer. J Mammary Gland Biol Neoplasia. 2002. 7(2): 201-208.
https://doi.org/10.1023/A:1020308104613
Schneider T., Gerhards R., Kirches E., Firsching R. Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J Neurooncol. 2001. 53(1): 39-46.
https://doi.org/10.1023/A:1011856406683
Luiten R.M., Kueter E.W., Mooi W. et al. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol. 2005. 23(35): 8978-8991.
https://doi.org/10.1200/JCO.2005.01.6816
Dillman R.O., Beutel L.D., De Leon C., Nayak S.K. Shortterm tumor cell lines from breast cancer for use as autologous tumor cell vaccines in the treatment of breast cancer. Cancer Biother Radiopharm. 2001. 16(3): 205-211.
https://doi.org/10.1089/10849780152389393
Dillman R.O., Wiemann M., Nayak S.K. et al. Interferongamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group. J Immunother. 2003. 26(4): 367-373.
https://doi.org/10.1097/00002371-200307000-00009
Shawler D.L., Bartholomew R.M., Garrett M.A. et al. Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine. Clin Exp Immunol. 2002. 129(1): 99-106.
https://doi.org/10.1046/j.1365-2249.2002.01863.x
Eaton J.D., Perry M.J., Nicholson S. et al. Allogeneic whole-cell vaccine: a phase I/II study in men with hormonerefractory prostate cancer. BJU Int. 2002. 89(1): 19-26.
https://doi.org/10.1046/j.1464-410X.2002.02572.x
Elliott G.T., McLeod R.A., Perez J. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine in the treatment of disseminated malignant melanoma. Semin Surg Oncol. 1993. 9(3): 264-272.
Vaishampayan U., Abrams J., Darrah D. et al. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Clin Cancer Res. 2002. 8(12); 3696-3701.
Arienti F., Sule-Suso J., Belli F. et al. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum Gene Ther. 1996. 7(16): 1955-1963.
https://doi.org/10.1089/hum.1996.7.16-1955
Maio M., Fonsatti E., Lamaj E. Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol Immunother. 2002. 51(1): 9-14.
https://doi.org/10.1007/s00262-001-0249-z
O'Rourke M.G., Johnson M., Lanagan C. et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother. 2003. 52(6): 387-395.
Katano M., Morisaki T., Koga K. et al. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas. Anticancer Res. 2005. 25(6A): 3771-3776.
Nestle F.O., Alijagic S., Gilliet M. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998. 4(3): 328-332.
https://doi.org/10.1038/nm0398-328
Lee W.C., Wang H.C., Hung C.F. et al. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother. 2005. 28(5): 496-504.
https://doi.org/10.1097/01.cji.0000171291.72039.e2
Yu J.S., Liu G., Ying H. et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004. 64(14): 4973-4979.
https://doi.org/10.1158/0008-5472.CAN-03-3505
Pandha H.S., John R.J., Hutchinson J. et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study. BJU Int. 2004. 94(3): 412-418.
https://doi.org/10.1111/j.1464-410X.2004.04922.x
Hirschowitz E.A., Foody T., Kryscio R. et al. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol. 2004. 22(14): 2808-2815.
https://doi.org/10.1200/JCO.2004.01.074
Avigan D., Vasir B., Gong J. et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res. 2004. 10(14): 4699-4708.
https://doi.org/10.1158/1078-0432.CCR-04-0347
Kugler A., Stuhler G., Walden P. et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med. 2000. 6(3): 332-336.
Srivastava P.K., Udono H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr Opin Immunol. 1994. 6(5): 728-732.
https://doi.org/10.1016/0952-7915(94)90076-0
Mazzaferro V., Coppa J., Carrabba M.G. et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res. 2003. 9(9): 3235-3245.
Ludewig B., Ochsenbein A.F., Odermatt B. et al. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med. 2000. 191(5): 795-804.
https://doi.org/10.1084/jem.191.5.795
Panelli M. C., Wunderlich J., Jeffries J. et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother. 2000. 23(4): 487-498.
https://doi.org/10.1097/00002371-200007000-00013
Zajchuk V.V., Potebnja G.P., Lisovenko G.S. ta in. Efektyvnist' zastosuvannja protypuhlynnoi' autovakcyny v kompleksnomu likuvanni hvoryh na rak molochnoi' zalozy II stadii'. Onkologija. 2004. 6(1): 52-58 [in Ukrainian].
Zatula D.G. Mikroorganizmy, rak i protivoopuholevyj immunitet. Kyiv: Nauk. dumka, 1985 [in Russian].
Kolesnik E.A., Potebnja G.P., Kikot' V.A. i dr. Protivoopuholevaja autovakcina v lechenii bol'nyh rasprostranennym kolorektal'nym rakom. Onkologija. 1999. 1(2): 104-109 [in Russian].
Potebnja G.P., Smolanka I.I., Lisovenko G.S. i dr. Jeffektivnost' immunoterapii autovakcinoj v lechenii bol'nyh rakom legkogo. Onkologija. 2000. 2(3): 191-194 [in Russian].
Potebnja G.P., Tanasijenko O.A., Lisovenko G.S., Savcova Z.D. Vykorystannja cytotoksychnyh lektyniv bakterial'nogo pohodzhennja v imunoterapii' eksperymental'nyh puhlyn. V: Struktura i biologichna aktyvnist' bakterial'nyh biopolimeriv. Kyiv: Kyi'vs'kyj universytet, 2003 : 235-304 [in Ukrainian].
Potebnja G.P., Skljar S.Ju., Bendjug G.D. ta in. Vykorystannja protypuhlynnoi' autovakcyny pry kompleksnomu likuvanni hvoryh na rak molochnoi' zalozy. Ukrhimioterap zhurnal. 2003. 17(2): 48-52 [in Ukrainian].
Chornyj V.O., Potebnja G.P., Lisovenko G.S. ta in. Perspektyvy zastosuvannja protypuhlynnoi' autovakcyny v likuvanni hvoryh na poshyrenyj rak shlunka. Onkologyja. 2003. 5(2): 107-110 [in Ukrainian].
Cmolanka I.I. Kombinovane likuvannja hvoryh na rak legeni. Avtoref. dys. d-ra byol.nauk: 14.01.07. Ynt onkologii' AMN Ukrai'ny. Kyi'v, 2001 [in Ukrainian].
Schulof R.S., Mai D., Nelson M.A. et al. Active specific immunotherapy with an autologous tumor cell vaccine in patients with resected non-small cell lung cancer. Mol Biother. 1988. 1(1): 30-36.
Butts C., Murray N., Maksymiuk A. et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol. 2005. 23(27): 6674-6681.
https://doi.org/10.1200/JCO.2005.13.011
Emens L.A., Reilly R.T., Jaffee E.M. Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocrine-Related Cancer. 2005. Vol. 12. P. 1-17.
https://doi.org/10.1677/erc.1.00671
Peoples G.E., Gurney J.M., Hueman M.T. et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol. 2005. 23(30): 7536-7545.
https://doi.org/10.1200/JCO.2005.03.047
Potebnja G.P., Skljar S.Ju., Bendjug G.D. ta in. Vlyjanye autovakcyni na pokazately ymmunnoj systemi y gormonal'nij gomeostaz pry kompleksnom lechenyy bol'nih rakom molochnoj zhelezi. Onkologija. 2004. 6(3): 175-179 [in Ukrainian].
Diederichsen A.C., Stenholm A.C., Kronborg O. et al. Immunization of colorectal cancer patients with autologous tumor cells. Oncol Rep. 1998. 5(4): 823-826.
Mosolits S., Ullenhag G., Mellstedt H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol. 2005. 16(6): 847-862.
https://doi.org/10.1093/annonc/mdi192
Potebnja G. P., Semernikov V. A., Hutornoj S. V. i dr. Vlijanie protivoopuholevoj autovakciny na nekotorye pokazateli immunnogo statusa bol'nyh s adenokarcinomoj prjamoj kishki. Jeksperim onkol. 2001. 23(3): 189-192 [in Russian].
Potebnja G. P., Semernikov V. A., Hutornoj S. V. i dr. Moduljacija antigennyh svojstv opuholevyh kletok s pomoshh'ju produktov metabolizma Bac. Mesentericus AB-56. Jeksperim onkol. 1999. 21(3-4): 223-227 [in Russian].
Potebnya G.P., Tanasienko O.A., Titova G.P. et al. Specifity and biological activity of cytotoxic lectins synthesized by Bacillus subtilis B-7025. Exp Oncol. 2002. 24(2): 150-152.
